Literature DB >> 9801334

Development of a fluorescent focus identification assay using serotype-specific monoclonal antibodies for detection and quantitation of rotaviruses in a tetravalent rotavirus vaccine.

D P Yang1, K M Goldberg, X D Ma, W Magargle, R Rappaport.   

Abstract

A fluorescent focus identification assay (FFIDA) was developed for use in experimental studies and for quantitation of the components in a tetravalent live oral rotavirus vaccine. The assay utilizes four serotype-specific neutralizing monoclonal antibodies (MAb) to detect and quantify individual rotaviruses by immunofluorescence staining of fixed virus-infected monkey kidney cells. In mixed virus infections, all four MAb, W1 (serotype 1), 1C10 (serotype 2), R1 (serotype 3), and S4 (serotype 4), specifically stain the relevant homologous serotype without exhibiting any cross-reactivity against the other serotypes. Furthermore, the test is sensitive enough to differentiate at least twofold (0.3 log) differences in virus titer. The results of testing four individual experimental vaccine lots three or more consecutive times showed that all four lots contained similar proportions of the four vaccine strains as detected by the classical plaque neutralization identification test. The rapidity and efficiency of the FFIDA are desirable attributes that make it suitable for use in studies requiring identification and quantitation of one or more of the four major rotavirus serotypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801334      PMCID: PMC96201          DOI: 10.1128/CDLI.5.6.780-783.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  9 in total

1.  Annual rotavirus epidemic patterns in North America. Results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. Rotavirus Study Group.

Authors:  C W LeBaron; J Lew; R I Glass; J M Weber; G M Ruiz-Palacios
Journal:  JAMA       Date:  1990 Aug 22-29       Impact factor: 56.272

2.  Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses.

Authors:  B S Coulson; L E Unicomb; G A Pitson; R F Bishop
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

3.  Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotype 1-, 2-, 3-, and 4-specific monoclonal antibodies to VP7.

Authors:  K Taniguchi; T Urasawa; Y Morita; H B Greenberg; S Urasawa
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

4.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.

Authors:  I de Zoysa; R G Feachem
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Infectivity assay of bovine rotavirus: evaluation of plaque and end-point methods in comparison with immunofluorescent cell assay.

Authors:  G Butchaiah
Journal:  Acta Virol       Date:  1988-01       Impact factor: 1.162

Review 6.  Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.

Authors:  A Z Kapikian; Y Hoshino; R M Chanock; I Pérez-Schael
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

7.  Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.

Authors:  I Pérez-Schael; M J Guntiñas; M Pérez; V Pagone; A M Rojas; R González; W Cunto; Y Hoshino; A Z Kapikian
Journal:  N Engl J Med       Date:  1997-10-23       Impact factor: 91.245

8.  Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.

Authors:  D I Bernstein; R I Glass; G Rodgers; B L Davidson; D A Sack
Journal:  JAMA       Date:  1995-04-19       Impact factor: 56.272

9.  Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.

Authors:  M B Rennels; R I Glass; P H Dennehy; D I Bernstein; M E Pichichero; E T Zito; M E Mack; B L Davidson; A Z Kapikian
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

  9 in total
  3 in total

1.  Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.

Authors:  Prashant Kumar; Ravi S Shukla; Ashaben Patel; Swathi R Pullagurla; Christopher Bird; Oluwadara Ogun; Ozan S Kumru; Ahd Hamidi; Femke Hoeksema; Christopher Yallop; Julie E Bines; Sangeeta B Joshi; David B Volkin
Journal:  Hum Vaccin Immunother       Date:  2021-04-16       Impact factor: 3.452

2.  Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions.

Authors:  Wonseok Kang; Eui-Cheol Shin
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

3.  Gene-edited vero cells as rotavirus vaccine substrates.

Authors:  Nichole Orr-Burks; Jackelyn Murray; Weilin Wu; Carl D Kirkwood; Kyle V Todd; Les Jones; Abhijeet Bakre; Houping Wang; Baoming Jiang; Ralph A Tripp
Journal:  Vaccine X       Date:  2019-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.